Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Arbutus Biopharma Corp(ABUS)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for ABUS
10/30/2026: ABUS (1-star) is currently NOT-A-BUY. Pass it for now.
Arbutus Biopharma is a clinical-stage biotechnology company focused on developing curative therapies for chronic hepatitis B (cHBV). Its primary business model combines a specialized drug-discovery pipeline with the strategic enforcement of its proprietary lipid nanoparticle (LNP) delivery technology. Recent patent settlement wins have significantly bolstered its cash position, enabling capital returns to shareholders and supporting ongoing clinical programs like imdusiran. While these successes reduce financial risk, the company faces inherent uncertainty from binary clinical trial outcomes and intense competition. It best suits investors comfortable with high-risk, high-reward biotechnology assets who are monitoring the advancement of its clinical pipeline and further intellectual property litigation results.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The potential for high growth exists if its curative HBV pipeline succeeds, but it is accompanied by high clinical risk. |
| Momentum investor | Strong fit while signal remains positive | The stock can experience significant momentum around major clinical catalysts or legal settlement news. |
| Value investor | Weak fit | Valuation is often tied to volatile intellectual property litigation outcomes and binary clinical trial results rather than traditional earnings. |
| Dividend investor | Weak fit | The company does not pay a regular dividend and focuses cash on R&D and capital returns via buybacks. |
| Low-risk investor | Weak fit | As a clinical-stage biotechnology company, it possesses high inherent volatility and risk. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock price reacts sharply to clinical trial updates, patent litigation news, and general biotech sector trends. |
| Valuation risk | High | Determining a fair value for a clinical-stage company with significant IP-based non-recurring revenue is difficult. |
| Competition risk (Hepatitis B therapy) | High | Larger companies with significant resources are simultaneously developing curative HBV therapies. |
| Business quality | Medium | While the company has strong IP, it relies heavily on successfully proving clinical efficacy for its lead assets. |
| Dividend income | Low / none | The company is not an income-generating vehicle for dividend-focused investors. |
| Execution risk | High | The company must manage complex clinical trials and ongoing global patent litigation simultaneously. |
Analysis of Past Performance
Type Stock | Historic Profit -10.75% | Avg. Invested days 38 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/30/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 656.02M USD | Price to earnings Ratio 5.42 | 1Y Target Price 5.47 |
Price to earnings Ratio 5.42 | 1Y Target Price 5.47 | ||
Volume (30-day avg) 6.1M shares | Beta 0.76 | 52 Weeks Range 3.50 - 5.45 | Updated Date 10/30/2026 |
52 Weeks Range 3.50 - 5.45 | Updated Date 10/30/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.79 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Infectious Disease Pipeline | Clinical development of HBV therapeutic candidates like imdusiran and AB-101. | Arbutus is a speculative clinical-stage company betting its future on the success of its Hepatitis B drug pipeline. |
| Intellectual Property Licensing | Royalties and settlements from the use of its Lipid Nanoparticle (LNP) technology by third-party pharmaceutical partners. | The company monetizes its specialized drug-delivery technology, which provides significant but often non-recurring cash flows. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Valuation
Trailing PE 5.42 | Forward PE 10.25 | Enterprise Value 765.69M | Price to Sales(TTM) 3.61 |
Enterprise Value 765.69M | Price to Sales(TTM) 3.61 | ||
Enterprise Value to Revenue 4.21 | Enterprise Value to EBITDA 5 | Shares Outstanding 153.28M | Shares Floating 150.53M |
Shares Outstanding 153.28M | Shares Floating 150.53M | ||
Percent Insiders 15.92 | Percent Institutions 67.31 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.